• Maia Biotechnology hit an enrollment milestone across ongoing Phase 2 THIO-101 and pivotal Phase 3 THIO-104 trials in non-small cell lung cancer.
• Interim Phase 2 results have already been presented, indicating the combination regimen kept more patients’ disease from worsening than chemotherapy.
• Phase 2 enrollment is complete for the cohort pairing ateganosine with cemiplimab, supporting the program’s path toward a readout.
• Phase 3 enrollment reached 65% of a 100-patient year-end goal, positioning the study for an interim analysis planned for 2027.
• FDA Fast Track status for ateganosine in NSCLC remains a key regulatory advantage as the company advances toward potential registration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070815PRIMZONEFULLFEED9840606) on October 07, 2026, and is solely responsible for the information contained therein.